BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36074674)

  • 1. The analysis of hormonal status and vascular and cell proliferation in endometrioid endometrial adenocarcinomas.
    Drocaş I; Crăiţoiu Ş; Stepan AE; Iliescu DG; Drocaş IA; Stepan MD
    Rom J Morphol Embryol; 2022; 63(1):113-120. PubMed ID: 36074674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
    Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
    Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
    Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Sep; 29(9):924-31. PubMed ID: 9744308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis?
    Gülseren V; Kocaer M; Özdemir İA; Çakır İ; Sancı M; Güngördük K
    Curr Probl Cancer; 2020 Feb; 44(1):100498. PubMed ID: 31395281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression.
    Sivridis E; Giatromanolaki A; Koukourakis M; Anastasiadis P
    Virchows Arch; 2001 May; 438(5):470-7. PubMed ID: 11407475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.
    Merritt WM; Kamat AA; Hwang JY; Bottsford-Miller J; Lu C; Lin YG; Coffey D; Spannuth WA; Nugent E; Han LY; Landen CN; Nick AM; Stone RL; Coffman K; Bruckheimer E; Broaddus RR; Gershenson DM; Coleman RL; Sood AK
    Cancer Biol Ther; 2010 Dec; 10(12):1306-14. PubMed ID: 20948320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer].
    Gottwald L; Kubiak R; Pasz-Walczak G; Sek P; Piekarski J; Szwalski J; Spych M; Chałubińska-Fendler J; Suzin J; Tyliński W; Jeziorski A
    Ginekol Pol; 2013 Feb; 84(2):95-101. PubMed ID: 23668054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lactoferrin immunoexpression in endometrial carcinomas: relationships with sex steroid hormone receptors (ER and PR), proliferation indices (Ki-67 and AgNOR) and survival.
    Giuffrè G; Arena F; Scarfì R; Simone A; Todaro P; Tuccari G
    Oncol Rep; 2006 Aug; 16(2):257-63. PubMed ID: 16820900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.
    Bonneterre J; Hutt E; Bosq J; Graham JD; Powell MA; Leblanc E; Fujiwara K; Herzog TJ; Coleman RL; Clarke CL; Gilles EM; Zukiwski AA; Monk BJ
    Gynecol Oncol; 2015 Sep; 138(3):663-7. PubMed ID: 26142884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.
    Kamat AA; Coffey D; Merritt WM; Nugent E; Urbauer D; Lin YG; Edwards C; Broaddus R; Coleman RL; Sood AK
    Cancer; 2009 Jun; 115(12):2684-92. PubMed ID: 19396818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
    Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
    Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
    J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
    Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of hPEBP4 negatively correlates with estrogen and progesterone receptors in endometrial carcinoma.
    Guo T; Li B; Gu C
    J BUON; 2013; 18(2):465-70. PubMed ID: 23818363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma.
    Jiang XF; Tang QL; Shen XM; Li HG; Chen LH; Wang XY; Luo X; Lin ZQ; Jiang GY
    Pathol Res Pract; 2012 Dec; 208(12):730-5. PubMed ID: 23122929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness of tissue microarray technique for the assessment of estrogen and progesterone receptors expression in endometrioid endometrial cancer--preliminary report].
    Gottwald L; Sek P; Kubiak R; Pasz-Walczak G; Piekarski J; Szwalski J; Suzin J; Tyliński W; Hendzel K; Jeziorski A
    Ginekol Pol; 2012 May; 83(5):342-6. PubMed ID: 22708330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.
    Zaino RJ; Brady WE; Todd W; Leslie K; Fischer EG; Horowitz NS; Mannel RS; Walker JL; Ivanovic M; Duska LR
    Int J Gynecol Pathol; 2014 Nov; 33(6):543-53. PubMed ID: 25272292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
    van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
    Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.